429 completed, 127 recruiting, 99 unknown, 75 terminated. 221 Not applicable, 196 Phase 2, 136 Phase 1, 90 Phase 3, 11 Phase 4.
Follow Muscular Disorders, Atrophic: new trials by email Literature Review of Muscular Disorders, Atrophic trials Research Report on Muscular Disorders, Atrophic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| iBCI Optimization for Veterans With Paralysis Mobile neural decoding platform (mobile iBCI) - Spinal Cord Injury, Amyotrophic Lateral Sclerosis | Not applicable | Not yet recruiting | VA Office of Research and Development | 2 | 2027-04-14 | 2026-11-16 |
| Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT) INTENT Neural Interface System - Tetraplegia/Tetraparesis, Amyotrophic Lateral Sclerosis (ALS) | Not applicable | Recruiting | Johns Hopkins University | 5 | 2027-01-01 | 2026-10-09 |
| A Study of SAT-3247 to Evaluate the Safety, Tolerability, and Efficacy in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) forazapadin, Placebo Comparator - Facioscapulohumeral Muscular Dystrophy (FSHD) | Phase 2 | Not yet recruiting | Satellos Bioscience, Inc. | 51 | 2026-12-15 | 2026-10-13 |
| Multimodal Study About Absence of Dp140 in Becker Muscular Dystrophy: Brain-muscle Imaging, Cognition and Muscle Function Becker Muscular Dystrophy | Not yet recruiting | Institut de Myologie, France | 75 | 2026-12-15 | 2026-11-03 | |
| Calcium Channel Blocker in Myotonic Dystrophy Type 1 Amlodipine - Myotonic Dystrophy 1 | Phase 1 | Not yet recruiting | University of Rochester | 20 | 2026-12-07 | 2026-11-09 |
| Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy Semaglutide (Rybelsus®), Placebo - Duchenne Muscular Dystrophy (DMD) | Phase 1 / Phase 2 | Recruiting | Vanderbilt University Medical Center | 30 | 2026-12-01 | 2026-11-12 |
| Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting ELEVIDYS, Sirolimus, Glucocorticoids - Duchenne Muscular Dystrophy | Phase 4 | Recruiting | Sarepta Therapeutics, Inc. | 20 | 2026-11-30 | 2026-11-12 |
| A Phase 2 Trial to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tegacorat in Male Participants 4 to <7 Years of Age With Duchenne Muscular Dystrophy Tegacorat - Duchenne Muscular Dystrophy (DMD) | Phase 2 | Not yet recruiting | Grünenthal GmbH | 36 | 2026-11-09 | 2026-11-03 |
| Urotherapy Education for Families of Children With Duchenne Muscular Dystrophy Urotherapy Education - Duchenne Muscular Dystrophy (DMD), Lower Urinary Tract Symptoms (LUTS) | Not applicable | Not yet recruiting | Lokman Hekim University | 50 | 2026-11-01 | 2026-09-15 |
| Metabolomic Biomarkers of Myotonic Dystrophy Myotonic Dystrophy Type 1 | Recruiting | Massachusetts General Hospital | 64 | 2026-10-26 | 2026-11-03 | |
| Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension DM1, Myotonic Dystrophy | Recruiting | Virginia Commonwealth University | 1000 | 2026-10-15 | 2026-10-16 | |
| Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy KER-065 - Duchenne Muscular Dystrophy | Phase 2 | Recruiting | Keros Therapeutics, Inc. | 36 | 2026-09-25 | 2026-11-13 |
| Personalized Disease Modeling for Rare Genetic Myopathies Congenital Myopathies, Muscular Dystrophy | Enrolling by invitation | Akron Children's Hospital | 3 | 2026-09-22 | 2026-11-03 | |
| Intermittent vs Alternate Daily Regimen of Prednisolone in Ambulatory Boys With Duchenne Muscular Dystrophy Alternate-day prednisolone, Intermittent prednisolone - Duchenne Muscular Dystrophy | Not applicable | Not yet recruiting | Muhammad Aamir Latif | 40 | 2026-09-15 | 2026-08-26 |
| A Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of SFL-0821 in Adults With FSHD SFL-0821 for injection, Placebo - Facioscapulohumeral Muscular Dystrophy (FSHD) | Phase 1 / Phase 2 | Recruiting | Soufflé Therapeutics, Inc. | 90 | 2026-09-01 | 2026-10-30 |
| A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping AOC 1044, Placebo - Muscular Dystrophies, Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy) | Phase 3 | Recruiting | Avidity Biosciences, Inc. | 70 | 2026-09-01 | 2026-11-10 |
| Self-Efficacy Enhancement Among Online Support Group of Primary Caregivers of Children With Neuro Muscular Dystrophy Multicomponent Intervention - Duchenne Muscular Dystrophy (DMD), Spinal Muscular Atrophy (SMA) | Not applicable | Active not recruiting | Aga Khan University | 34 | 2026-08-15 | 2026-10-09 |
| An Ambispective Natural History Study in Myotonic Dystrophy Patients Linking Retrospective Data Captured From the DM-Scope Registry With a Prospective 24-month Follow-up Period Myotonic Dystrophy 1, Myotonic Dystrophy 2 | Not yet recruiting | Lupin Ltd. | 100 | 2026-08-03 | 2026-07-28 | |
| Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE) ENTR-601-44, ENTR-601-45 - Duchenne Muscular Dystrophy (DMD) | Phase 2 | Not yet recruiting | Entrada Therapeutics, Inc. | 80 | 2026-08-01 | 2026-07-02 |
| Effect of Knee Position on Muscle Loss During Leg Immobilization Knee immobilization brace (0°) for 5 days, Knee immobilization brace (60°) for 5 days - Muscle Atrophy, Disuse Atrophy | Not applicable | Recruiting | Wageningen University | 30 | 2026-08-01 | 2026-11-13 |
Showing 20 of 878. Sign in to see all of them.
Muscular Dystrophy, Duchenne (480) · Muscular Dystrophies (224) · Myotonic Dystrophy (126) · Muscular Dystrophy, Facioscapulohumeral (75) · Neuromuscular Diseases (74) · Muscular Dystrophies, Limb-Girdle (46) · Muscular Diseases (41) · Muscular Atrophy, Spinal (32) · Amyotrophic Lateral Sclerosis (30) · Postpoliomyelitis Syndrome (28) · Spinal Cord Injuries (27) · Musculoskeletal Diseases (26) · Motor Activity (25) · Genetic Diseases, Inborn (22)
Nervous System Diseases (857) · Musculoskeletal Diseases (852) · Muscular Diseases (837) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (816) · Neuromuscular Diseases (804) · Genetic Diseases, Inborn (795) · Muscular Dystrophies (591) · Genetic Diseases, X-Linked (480) · Neurodegenerative Diseases (206) · Heredodegenerative Disorders, Nervous System (148) · Myotonic Disorders (126) · Central Nervous System Diseases (110) · Pathological Conditions, Signs and Symptoms (110) · Spinal Cord Diseases (87)
ataluren (13) · eteplirsen (12) · Exercise (11) · Prednisone (11) · VBP15 compound (9) · deflazacort (8) · Tadalafil (7) · Sodium Chloride (6) · givinostat (6) · givinostat hydrochloride (6) · idebenone (6) · Adrenal Cortex Hormones (5) · Physical Therapy Modalities (5) · casimersen (5) · golodirsen (5)
Sarepta Therapeutics, Inc. (38) · Hacettepe University (22) · PTC Therapeutics (19) · Cooperative International Neuromuscular Research Group (16) · Assistance Publique - Hôpitaux de Paris (14) · Copenhagen University Hospital, Rigshospitalet (14) · Avidity Biosciences, Inc. (11) · BioMarin Pharmaceutical (11) · University of Rochester (11) · National Institute of Neurological Disorders and Stroke (NINDS) (10) · Nationwide Children's Hospital (10) · University of Florida (10) · Virginia Commonwealth University (10) · NS Pharma, Inc. (9) · Santhera Pharmaceuticals (9)
United States (394) · France (130) · United Kingdom (126) · Canada (123) · Italy (122) · Spain (85) · Turkey (Türkiye) (81) · Germany (70) · Belgium (68) · Netherlands (68) · Australia (56) · Denmark (45) · Israel (37) · Sweden (33) · Japan (32)
Nicholas Johnson, MD (6) · Craig McDonald, MD (5) · Kevin Flanigan, MD (5) · Paula R Clemens, MD (5) · Ronald G Victor, MD (5) · Diana M Escolar, MD (4) · Dirk Fischer, MD (4) · Francesco Bibbiani, MD (4) · Mark Awadalla (4) · Carlos BM Monteiro, Ph.D. (3)
PMID 32956407, PMID 37539981, PMID 41671094, PMID 42613652, PMID 24919692, PMID 26573217, PMID 27358494, PMID 32434278, PMID 32522498, PMID 32851872, PMID 34693725, PMID 34779542, PMID 35794169, PMID 38190001, PMID 38521535, PMID 38753764, PMID 40152935, PMID 41058127, PMID 41774261, PMID 42139656, PMID 42202243, PMID 10025486, PMID 10747199, PMID 10826123, PMID 10836341, PMID 1108172, PMID 11751186, PMID 11972163, PMID 12030525, PMID 12122118, PMID 12210323, PMID 12351998, PMID 12409823, PMID 1281472, PMID 13997180, PMID 14510658, PMID 14760317, PMID 15293280, PMID 15302625, PMID 15781190, PMID 1580445, PMID 15984021, PMID 16055882, PMID 16267188, PMID 16602102, PMID 16713921, PMID 16763895, PMID 16763896, PMID 16849828, PMID 16900450
2023 (12), 2015 (8), 2019 (7), 2025 (6), 2016 (5), 2017 (4), 2014 (3), U54NS048843 (3), 2008 (2), 2009 (2), R44NS095423 (2), U34AR068616 (2), 1DP2DC021055 (1), 2018 (1), 2026A (1)